Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 May;57(5):1133-1141.
doi: 10.1111/trf.14003. Epub 2017 Feb 24.

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

Elizabeth S Allen  1 , David F Stroncek  1 , Jiaqiang Ren  1 , Anne F Eder  1 , Kamille A West  1 , Terry J Fry  2 , Daniel W Lee  3 , Crystal L Mackall  2 , Cathy Conry-Cantilena  1
Affiliations
Clinical Trial

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

Elizabeth S Allen et al. Transfusion. 2017 May.

Abstract

Background: The first step in manufacturing chimeric antigen receptor (CAR) T cells is to collect autologous CD3+ lymphocytes by apheresis. Patients, however, often have leukopenia or have other disease-related complications. We evaluated the feasibility of collecting adequate numbers of CD3+ cells, risk factors for inadequate collections, and the rate of adverse events.

Study design and methods: Apheresis lymphocyte collections from patients participating in three CAR T-cell clinical trials were reviewed. Collections were performed on the COBE Spectra by experienced nurses, with the goal of obtaining a minimum of 0.6 × 109 and a target of 2 × 109 CD3+ cells. Preapheresis peripheral blood counts, apheresis parameters, and product cell counts were analyzed.

Results: Of the 71 collections, 69 (97%) achieved the minimum and 55 (77%) achieved the target. Before apheresis, the 16 patients with yields below the target had significantly lower proportions and absolute numbers of circulating lymphocytes and CD3+ lymphocytes and higher proportions of circulating blasts and NK cells than those who achieved the target (470 × 106 lymphocytes/L vs. 1340 × 106 lymphocytes/L, p = 0.008; 349 × 106 CD3+ cells/L vs. 914 × 106 CD3+ cells/L, p = 0.001; 17.6% blasts vs. 4.55% blasts, p = 0.029). Enrichment of blasts in the product compared to the peripheral blood occurred in four patients, including the two patients whose collections did not yield the minimum number of CD3+ cells. Apheresis complications occurred in 11 patients (15%) and, with one exception, were easily managed in the apheresis clinic.

Conclusions: In most patients undergoing CAR T-cell therapy, leukapheresis is well tolerated, and adequate numbers of CD3+ lymphocytes are collected.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Apheresis CD3+ cell collection yield
Panel A. Total CD3+ cell yield by diagnosis. Each circle represents 1 patient. Panel B. CD3+ cell yield per liter of blood processed versus pre-apheresis CD3+ count. Using the pre-procedure CD3+ count (cells/μL) as the independent variable, x, the collection yield (CD3+ cells per L processed) can be estimated by the equation y=469394x + 108 (R=0.8613; R2=0.7419). Patients with acute leukemia are represented by closed diamonds, patients with solid tumors by open diamonds.
Figure 1
Figure 1. Apheresis CD3+ cell collection yield
Panel A. Total CD3+ cell yield by diagnosis. Each circle represents 1 patient. Panel B. CD3+ cell yield per liter of blood processed versus pre-apheresis CD3+ count. Using the pre-procedure CD3+ count (cells/μL) as the independent variable, x, the collection yield (CD3+ cells per L processed) can be estimated by the equation y=469394x + 108 (R=0.8613; R2=0.7419). Patients with acute leukemia are represented by closed diamonds, patients with solid tumors by open diamonds.
Figure 2
Figure 2. Comparison of absolute lymphocyte counts and peripheral blood NK cell (%) before apheresis in patients with below- and above-target CD3+ cell yields
Each circle represents 1 patient. The targeted yield was 2×109 CD3+ cells. Panel A. Absolute lymphocyte count in patients with below- and above-target CD3+ cell yields. A single patient with a yield above the target whose absolute lymphocyte count was 8.29×103/μL was not included. Panel B. Peripheral blood NK cells (%) in patients with below- and above-target CD3+ cell yields.
Figure 2
Figure 2. Comparison of absolute lymphocyte counts and peripheral blood NK cell (%) before apheresis in patients with below- and above-target CD3+ cell yields
Each circle represents 1 patient. The targeted yield was 2×109 CD3+ cells. Panel A. Absolute lymphocyte count in patients with below- and above-target CD3+ cell yields. A single patient with a yield above the target whose absolute lymphocyte count was 8.29×103/μL was not included. Panel B. Peripheral blood NK cells (%) in patients with below- and above-target CD3+ cell yields.
Figure 3
Figure 3. CD3+ cell collection yield vs total blood volumes processed
Each diamond represents 1 patient. Only the 16 patients whose collections yielded fewer than 2×109 CD3+ cells are depicted.
Figure 4
Figure 4. Difference in blast percentages in the apheresis product versus peripheral blood
Each circle represents 1 patient. Only those with circulating blasts on the day of collection are depicted.
See this image and copyright information in PMC

Comment in

References

    1. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2015 - PubMed
    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. - PMC - PubMed
    1. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–28. - PMC - PubMed
    1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18. - PMC - PubMed
    1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38. - PMC - PubMed

Publication types